 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
P1 data, Journal: Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. (Pubmed Central) - Apr 4, 2023
P1
SB-121 was safe and well tolerated. SB-121-associated directional improvements in adaptive behavior measured by Vineland-3 and social preference as measured with eye tracking were noted.Trial registration: clinicaltrials.gov Identifier: NCT04944901.
- || lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
Trial completion: SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex (clinicaltrials.gov) - Mar 17, 2022
P1, N=15, Completed, Sponsor: Scioto Biosciences, Inc.
SB-121-associated directional improvements in adaptive behavior measured by Vineland-3 and social preference as measured with eye tracking were noted.Trial registration: clinicaltrials.gov Identifier: NCT04944901. Recruiting --> Completed
- | lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
Trial completion date, Trial primary completion date: SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex (clinicaltrials.gov) - Nov 11, 2021
P1, N=16, Recruiting, Sponsor: Scioto Biosciences, Inc.
Recruiting --> Completed Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
- || lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
Enrollment open: SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex (clinicaltrials.gov) - Jul 12, 2021
P1, N=16, Recruiting, Sponsor: Scioto Biosciences, Inc.
Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Nov 2021 --> Apr 2022 Not yet recruiting --> Recruiting
- | lactobacillus reuteri (SB-121) / Scioto Biosci, Genome & Company
New P1 trial: SBI-SB121-20-01: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex (clinicaltrials.gov) - Jun 30, 2021
P1, N=16, Not yet recruiting, Sponsor: Scioto Biosciences, Inc.